{"title":"Manganese superoxide dismutase polymorphism and prostate cancer risk: a meta-analysis","authors":"Bingbing Wei , Yunyun Zhang , Bo Xi , Jiantang Su","doi":"10.1016/S1007-4376(09)60081-2","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>MnSOD plays a vital role in carcinogenesis, partly in that it converts superoxide radical to oxygen and hydrogen peroxide. The conflicting results of studies on the role of MnSOD polymorphism (Val−9Ala) with the risk of prostate cancer encouraged us to perform a meta-analysis to examine the association.</p></div><div><h3>Methods</h3><p>A comprehensive search was conducted to examine all the eligible studies of MnSOD polymorphism and prostate cancer risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. The pooled estimates of ORs were computed using the fixed-effects model or random- effects model.</p></div><div><h3>Results</h3><p>Ten eligible studies, including 4 608 cases and 5 861 controls, were included in this meta-analysis. Overall, individuals with Ala/Ala and Ala/Val genotypes have an increased risk of prostate cancer, compared with those carrying the Val/Val genotype (Ala/Ala vs. Val/Val: OR=1.13; 95% CI=1.02∼1.25; <em>P</em> = 0.020, P<sub>heterogeneity</sub>=0.370; Ala/Val vs. Val/Val: OR=1.14; 95% CI=1.04∼1.25; <em>P</em> = 0.004, P<sub>heterogeneity</sub>=0.940). This significant association was also found in a dominant model with −9Ala allele (Ala/Ala+Ala/Val vs. Val/Val: OR=1.12; 95% CI: 1.03∼1.22; <em>P</em> = 0.009, P<sub>heterogeneity</sub>=0.64). In the subgroup by ethnicity, it was observed that significantly elevated prostate cancer risk was associated with −9Ala allele in Caucasians (Ala/Ala vs. Val/Val: OR=1.14; 95% CI=1.03∼1.27; <em>P</em> = 0.01, P<sub>heterogeneity</sub>=0.31; Ala/Val vs. Val/Val: OR=1.14; 95% CI=1.04∼1.24; <em>P</em> = 0.006, P<sub>heterogeneity</sub>=0.87) but not in African-Americans. Furthermore, this meta-analysis showed that the −9Ala allele was associated with both nonaggressive and aggressive prostate cancer risks.</p></div><div><h3>Conclusion</h3><p>Our meta-analysis suggests that MnSOD Val−9Ala polymorphism is associated with prostate cancer risk, especially in Caucasians.</p></div>","PeriodicalId":100807,"journal":{"name":"Journal of Nanjing Medical University","volume":"23 5","pages":"Pages 340-346"},"PeriodicalIF":0.0000,"publicationDate":"2009-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1007-4376(09)60081-2","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nanjing Medical University","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1007437609600812","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Objective
MnSOD plays a vital role in carcinogenesis, partly in that it converts superoxide radical to oxygen and hydrogen peroxide. The conflicting results of studies on the role of MnSOD polymorphism (Val−9Ala) with the risk of prostate cancer encouraged us to perform a meta-analysis to examine the association.
Methods
A comprehensive search was conducted to examine all the eligible studies of MnSOD polymorphism and prostate cancer risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. The pooled estimates of ORs were computed using the fixed-effects model or random- effects model.
Results
Ten eligible studies, including 4 608 cases and 5 861 controls, were included in this meta-analysis. Overall, individuals with Ala/Ala and Ala/Val genotypes have an increased risk of prostate cancer, compared with those carrying the Val/Val genotype (Ala/Ala vs. Val/Val: OR=1.13; 95% CI=1.02∼1.25; P = 0.020, Pheterogeneity=0.370; Ala/Val vs. Val/Val: OR=1.14; 95% CI=1.04∼1.25; P = 0.004, Pheterogeneity=0.940). This significant association was also found in a dominant model with −9Ala allele (Ala/Ala+Ala/Val vs. Val/Val: OR=1.12; 95% CI: 1.03∼1.22; P = 0.009, Pheterogeneity=0.64). In the subgroup by ethnicity, it was observed that significantly elevated prostate cancer risk was associated with −9Ala allele in Caucasians (Ala/Ala vs. Val/Val: OR=1.14; 95% CI=1.03∼1.27; P = 0.01, Pheterogeneity=0.31; Ala/Val vs. Val/Val: OR=1.14; 95% CI=1.04∼1.24; P = 0.006, Pheterogeneity=0.87) but not in African-Americans. Furthermore, this meta-analysis showed that the −9Ala allele was associated with both nonaggressive and aggressive prostate cancer risks.
Conclusion
Our meta-analysis suggests that MnSOD Val−9Ala polymorphism is associated with prostate cancer risk, especially in Caucasians.